tiprankstipranks
Anebulo Pharmaceuticals (ANEB)
NASDAQ:ANEB
Holding ANEB?
Track your performance easily

Anebulo Pharmaceuticals (ANEB) Income Statement

19 Followers

Anebulo Pharmaceuticals Income Statement

Last quarter (Q1 2025), Anebulo Pharmaceuticals's total revenue was $―, a decrease of ― from the same quarter last year. In Q1, Anebulo Pharmaceuticals's net income was $-2.20M. See Anebulo Pharmaceuticals’s key income statements, including revenue, expenses, profit, and income.
Income Statement
TTM
Jun 24Jun 23Jun 22Jun 21Jun 20
Total Revenue
-----$ 0.00
Cost of Revenue
------
Gross Profit
------
Operating Expense
$ 8.18M$ 8.31M$ 11.78M$ 6.83M$ 3.61M$ 173.35K
Operating Income
$ -8.18M$ -8.31M$ -11.78M$ -6.83M$ -3.61M$ -173.35K
Net Non Operating Interest Income Expense
$ 219.83K$ 249.02K$ 92.41K$ 7.33K$ -10.75K$ -1.29K
Other Income Expense
$ -1.32K$ -9.26K$ 41.15K$ -1.78K$ 26.63M-
Pretax Income
$ -7.96M$ -8.05M$ -11.73M$ -6.83M$ -30.25M$ -174.64K
Tax Provision
-----$ 0.00
Earnings From Equity Interest Net Of Tax
----$ -8.21M-
Net Income Common Stockholders
$ -7.92M$ -8.20M$ -11.73M$ -6.83M$ -38.46M$ -174.64K
Basic EPS
$ -0.30$ -0.32$ -0.47$ -0.29$ -2.83$ >-0.01
Diluted EPS
$ -0.30$ -0.32$ -0.47$ -0.29$ -2.83$ >-0.01
Basic Average Shares
$ 103.59M$ 25.82M$ 25.07M$ 23.34M$ 13.61M$ 23.27M
Diluted Average Shares
$ 103.59M$ 25.82M$ 25.07M$ 23.34M$ 13.61M$ 23.27M
Dividend Per Share
------
Total Operating Income As Reported
------
Reported Normalized Basic E P S
------
Reported Normalized Diluted E P S
------
Rent Expense Supplemental
------
Total Expenses
$ 8.18M$ 8.31M$ 11.78M$ 6.83M$ 3.61M$ 173.35K
Net Income From Continuing And Discontinued Operation
$ -7.92M$ -8.20M$ -11.73M$ -6.83M$ -30.25M$ -174.64K
Normalized Income
$ -8.07M$ -6.36M-$ -5.39M$ -23.90M$ -174.64K
Interest Expense
-----$ 1.29K
EBIT
$ -7.95M$ -8.20M$ -11.73M$ -6.83M$ -30.24M$ -173.35K
EBITDA
$ -7.77M$ -8.05M$ -11.73M$ -6.83M$ -30.24M$ -173.35K
Currency in USD

Anebulo Pharmaceuticals Earnings and Revenue History

What am I Missing?
Make informed decisions based on Top Analysts' activity
Know what industry insiders are buying
Get actionable alerts from top Wall Street Analysts
Find out before anyone else which stock is going to shoot up
Get powerful stock screeners & detailed portfolio analysis